Abstract
Randomized trials performed in anthracycline-pretreated breast cancer patients have demonstrated good activity of taxane-based regimens. In a face to face comparison, single-agent docetaxel proved to be significantly more effective than paclitaxel. Treatment with docetaxel was also associated with an increased incidence of grade grade-3/4 toxicities in this trial. Antitumor activity of taxane-based combination regimens was clearly superior to single-agent therapy in two trials. As anticipated, treatment-associated toxicity was greater with combination regimens, but this did not affect quality of life.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Publikationsform: | Publisher's Version |
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
URN: | urn:nbn:de:bvb:19-epub-16472-6 |
ISSN: | 0378-584X |
Allianz-/Nationallizenz: | Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. |
Sprache: | Deutsch |
Dokumenten ID: | 16472 |
Datum der Veröffentlichung auf Open Access LMU: | 29. Aug. 2013, 09:56 |
Letzte Änderungen: | 04. Nov. 2020, 12:57 |